Article Text

Download PDFPDF
Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer
  1. Julia Rose Salinaro1,
  2. Kourtnie McQuillen2,
  3. Megan Stemple2,
  4. Robert Boccaccio3,
  5. Jessie Ehrisman4,
  6. Amelia M Lorenzo4,
  7. Laura Havrilesky4,
  8. Angeles Alvarez Secord4,
  9. Valerie Galvan Turner2,
  10. Kathleen Nadine Moore3 and
  11. Brittany Davidson4
  1. 1 Obstetrics and Gynecology, Duke University Health System, Durham, North Carolina, USA
  2. 2 West Virginia University, Morgantown, West Virginia, USA
  3. 3 Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
  4. 4 Gynecologic Oncology, Duke University Health System, Durham, North Carolina, USA
  1. Correspondence to Dr Brittany Davidson, Gynecologic Oncology, Duke University Health System, Durham, NC 27710, USA; brittany.davidson{at}duke.edu

Abstract

Objectives Neoadjuvant chemotherapy may be considered for women with epithelial ovarian cancer who have poor performance status or a disease burden not amenable to primary cytoreductive surgery. Overlap exists between indications for neoadjuvant chemotherapy and known risk factors for venous thromboembolism, including impaired mobility, increasing age, and advanced malignancy. The objective of this study was to determine the rate of venous thromboembolism among women receiving neoadjuvant chemotherapy for epithelial ovarian cancer.

Methods A multi-institutional, observational study of patients receiving neoadjuvant chemotherapy for primary epithelial ovarian, fallopian tube, or peritoneal cancer was conducted. Primary outcome was rate of venous thromboembolism during neoadjuvant chemotherapy. Secondary outcomes included rates of venous thromboembolism at other stages of treatment (diagnosis, following interval debulking surgery, during adjuvant chemotherapy, or during treatment for recurrence) and associations between occurrence of venous thromboembolism during neoadjuvant chemotherapy, subject characteristics, and interval debulking outcomes. Venous thromboembolism was defined as deep vein thrombosis in the upper or lower extremities or in association with peripherally inserted central catheters or ports, pulmonary embolism, or concurrent deep vein thrombosis and pulmonary embolism. Both symptomatic and asymptomatic venous thromboembolism were reported.

Results A total of 230 patients receiving neoadjuvant chemotherapy were included; 63 (27%) patients overall experienced a venous thromboembolism. The primary outcome of venous thromboembolism during neoadjuvant chemotherapy occurred in 16 (7.7%) patients. Of the remaining venous thromboembolism events, 22 were at diagnosis (9.6%), six post-operatively (3%), five during adjuvant chemotherapy (3%), and 14 during treatment for recurrence (12%). Patients experiencing a venous thromboembolism during neoadjuvant chemotherapy had a longer mean time to interval debulking and were less likely to undergo optimal cytoreduction (50% vs 80.2%, p=0.02).

Conclusions Patients with advanced ovarian cancer are at high risk for venous thromboembolism while receiving neoadjuvant chemotherapy. Consideration of thromboprophylaxis may be warranted.

  • ovarian cancer
  • venous thromboembolism
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors JRS: manuscript author, data abstraction and compilation, statistical analysis. KM: aided in development of neoadjuvant chemotherapy database at West Virginia University, assisted in data abstraction. MS: assisted in data abstraction for West Virginia University. RB: aided in development of neoadjuvant chemotherapy database at the University of Oklahoma, data abstraction. JE: assisted in development of neoadjuvant chemotherapy database at Duke University, data abstraction, patient consent. AML: maintenance of neoadjuvant chemotherapy database at Duke University, patient consent, coordination of data sharing among all three institutions. LJH: manuscript review and editing. AAS: leader of neoadjuvant chemotherapy database at Duke University, manuscript review and editing. VGT: leader of neoadjuvant chemotherapy database at West Virginia University. KNM: leader of neoadjuvant chemotherapy database at the University of Oklahoma. BAD: assisted in development of neoadjuvant chemotherapy database at Duke University, coordination of multiple institutions, data abstraction, manuscript review and editing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.